
    
      This study will consist of 52-week treatment period and a 4-week follow-up period. 52-week
      treatment period comprises of a 26-week treatment period A (Day 0 to Day 182) and a 26-week
      treatment period B (Day 183 to Day 364). Participants who complete treatment period A will
      immediately continue into treatment period B. After completion of treatment period B
      participants may roll over into an expanded access study TAK-743-5007. Participants who elect
      to rollover to Study TAK-743-5007 will complete their end of study (EOS) assessments on Day
      378. All other participants will complete their EOS assessments on Day 392.
    
  